Wealthcare Advisory Partners LLC Purchases Shares of 4,672 Insmed, Inc. $INSM

Wealthcare Advisory Partners LLC purchased a new stake in shares of Insmed, Inc. (NASDAQ:INSM) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 4,672 shares of the biopharmaceutical company’s stock, valued at approximately $498,000.

A number of other hedge funds also recently made changes to their positions in the business. iA Global Asset Management Inc. grew its position in Insmed by 15,973.5% in the 4th quarter. iA Global Asset Management Inc. now owns 26,682 shares of the biopharmaceutical company’s stock valued at $4,644,000 after buying an additional 26,516 shares in the last quarter. Monashee Investment Management LLC bought a new stake in shares of Insmed during the 4th quarter worth about $8,702,000. Universal Beteiligungs und Servicegesellschaft mbH raised its position in shares of Insmed by 89.5% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 103,308 shares of the biopharmaceutical company’s stock worth $17,981,000 after buying an additional 48,779 shares in the last quarter. Danske Bank A S raised its position in shares of Insmed by 4,494.1% during the 4th quarter. Danske Bank A S now owns 110,258 shares of the biopharmaceutical company’s stock worth $19,189,000 after buying an additional 107,858 shares in the last quarter. Finally, PKO Investment Management Joint Stock Co acquired a new stake in shares of Insmed in the 4th quarter worth approximately $1,967,000.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on INSM shares. Royal Bank Of Canada decreased their price objective on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a report on Friday, June 5th. BMO Capital Markets began coverage on Insmed in a report on Monday, July 20th. They set an “outperform” rating and a $192.00 target price on the stock. Jefferies Financial Group restated a “buy” rating and issued a $175.00 target price on shares of Insmed in a research report on Thursday, August 6th. Mizuho set a $192.00 price target on Insmed in a research note on Tuesday, June 16th. Finally, HC Wainwright reiterated a “buy” rating on shares of Insmed in a research report on Monday, August 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $205.52.

Insmed Trading Down 2.1%

Insmed stock opened at $123.74 on Friday. The firm has a market cap of $27.02 billion, a price-to-earnings ratio of -30.11 and a beta of 0.81. Insmed, Inc. has a 1 year low of $90.39 and a 1 year high of $212.75. The firm’s 50 day moving average price is $107.88 and its two-hundred day moving average price is $128.20. The company has a debt-to-equity ratio of 0.74, a quick ratio of 3.40 and a current ratio of 3.72.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.61. The company had revenue of $425.49 million during the quarter, compared to the consensus estimate of $395.50 million. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The company’s quarterly revenue was up 296.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.70) EPS. On average, research analysts predict that Insmed, Inc. will post -1.83 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Michael Alexander Smith sold 1,806 shares of Insmed stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $95.82, for a total value of $173,050.92. Following the transaction, the insider owned 37,648 shares of the company’s stock, valued at approximately $3,607,431.36. This trade represents a 4.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Sara Bonstein sold 2,404 shares of Insmed stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $245,857.08. Following the completion of the transaction, the chief financial officer directly owned 69,082 shares in the company, valued at $7,065,016.14. This represents a 3.36% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 294,440 shares of company stock valued at $37,758,548 over the last ninety days. 2.10% of the stock is currently owned by company insiders.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.